Home / Category / Health & Medical / Pharmaceuticals

Pharmaceuticals News

Investments & Funding;Renewable Energy;Pharmaceuticals

World Bank approves $500 million Morocco loan for jobs and green growth reforms

The World Bank has approved a $500 million financing package for Morocco under its First Jobs and Green Growth Development Policy Loan. The programme supports labour market reforms, SME development, clean energy investment, and pharmaceutical export expansion, with targets including 330,000 job seekers and over 40,000 new childcare places.

Morocco | 3 days ago

Pharmaceuticals

Shionogi secures up to $482 million BARDA contract for Fetroja antibiotic production in US

Shionogi Inc. has been awarded a BARDA Project BioShield contract initially funded at $119 million, with options up to $482 million, to establish US manufacturing for antibiotic Fetroja and expand its use against biothreat pathogens including plague and melioidosis.

3 days ago • Japan;United States

Pharmaceuticals

USDA awards $2 million to Purdue-led team for catmint-based HPAI fogging technology

The USDA APHIS has granted $2 million to a Purdue University-led research team, including Entomol and 1,4Group, to test a hydrogenated catmint oil fogging technology against highly pathogenic avian influenza (HPAI) in poultry environments.

3 days ago • United States

Pharmaceuticals

Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9 billion rare disease expansion

Neurocrine Biosciences has agreed to purchase Soleno Therapeutics for $53.00 per share in cash. The $2.9 billion deal centers on VYKAT XR, a first-in-class treatment for Prader-Willi syndrome that generated $190 million in 2025, significantly bolstering Neurocrine’s endocrinology and rare disease portfolio.

3 days ago • United States

Pharmaceuticals

Biogen to acquire Apellis for USD 5.6 billion to strengthen immunology and rare disease portfolio

Biogen has agreed to acquire Apellis Pharmaceuticals in a USD 5.6 billion cash deal, adding two revenue-generating therapies to its portfolio. The transaction is expected to accelerate growth in immunology and rare diseases while enhancing Biogen’s commercial and pipeline capabilities.

3 days ago • United States

Pharmaceuticals

India scales AYUSH R&D ecosystem through AYURGYAN scheme to strengthen evidence-based Ayurveda

The Government of India is expanding research, training, and innovation in Ayurveda under the AYURGYAN scheme, supporting multiple R&D projects and institutional capacity building to improve scientific validation, global acceptance, and commercialization prospects of traditional medicine systems.

3 days ago • India

Pharmaceuticals

Strides acquires Sandoz branded generics portfolio to expand Sub-Saharan Africa footprint

Strides Pharma has agreed to acquire a portfolio of branded generic products from Sandoz across Sub-Saharan Africa, covering anti-infective, cardiovascular, and dermatology segments. The $12 million deal spans four key markets and includes both full acquisition and continued marketing rights, positioning Strides among the region's top five pharmaceutical companies.

3 days ago • Sub Saharan Africa;Nigeria

Pharmaceuticals

GSK divests rare disease asset to Alfasigma in deal valued up to $690 million

GSK has entered a licence agreement with Alfasigma for the worldwide rights to linerixibat, an investigational treatment for cholestatic pruritus in primary biliary cholangitis. The deal includes an upfront payment of $300 million and potential milestones, reflecting strategic portfolio prioritisation as GSK focuses on other liver disease programmes.

3 days ago • United States

Pharmaceuticals

Blue Jet Healthcare to invest ₹23 billion in Andhra Pradesh pharma complex targeting FY29 commissioning

Blue Jet Healthcare will invest approximately ₹23 billion to establish a greenfield pharmaceutical manufacturing complex in Andhra Pradesh’s Rambilli Industrial Park. The phased project, expected to be operational by FY2028–29, will expand capacity for contrast media intermediates and specialty chemicals while creating 2,000 jobs.

3 days ago • India

Pharmaceuticals

Pfizer enters exclusive global agreement with YaoPharma for GLP-1 obesity drug candidate

Pfizer has entered an exclusive global licensing agreement with YaoPharma for YP05002, an oral GLP-1 receptor agonist in Phase 1 for chronic weight management. The deal includes a USD 150 million upfront payment and potential milestone payments of up to USD 1.935 billion.

3 days ago • China;United States

Latest News

Energy & Power | 3 days ago

EBRD approves USD 65 million for Egypt’s solar-plus-storage infrastructure project

The European Bank for Reconstruction and Development has committed USD 65 million to finance a hybrid 200 MW solar plant and 120 MWh battery storage facility in Aswan, Egypt. This initiative, developed by HAU Energy, marks a critical step in stabilizing the national grid while advancing the country's transition toward a low-carbon energy infrastructure.

Infrastructure | 3 days ago

USACE awards $113.8 million contract to J.F. Brennan for invasive carp deterrents at Brandon road project

The U.S. Army Corps of Engineers has awarded a $113.8 million contract to J.F. Brennan Company for leading-edge invasive carp deterrents as part of the Brandon Road Interbasin Project in Illinois. The award completes Increment I of the ecosystem restoration effort.

Energy & Power | 3 days ago

CoreMarine and Jumbo Offshore win contract for FLNG mooring installation in Argentina

CoreMarine and Jumbo Offshore have secured a contract from Southern Energy S.A. to transport, install, and hook up soft-yoke mooring systems for two FLNG vessels in Golfo San Matías. The project supports Argentina’s gas export expansion, with installations scheduled for 2027 and 2028.

Government & Policy | 3 days ago

NASA awards $76m data science contract to Development Seed for Marshall space flight center

NASA has selected Development Seed for a $76 million indefinite-delivery/indefinite-quantity contract to provide R&D services to the Office of Data Science and Informatics at Marshall Space Flight Center. The contract includes a two-year base period with three one-year options through June 2031.